Conclusions

Genome-wide transcriptome profiling of data from the INMARK trial identified nine genes that were downregulated after 12 weeks of treatment with nintedanib in subjects with IPF and preserved lung function at baseline.
Pathways analysis suggested that the downregulated genes are related to neutrophil function, extracellular matrix organization and antibacterial/antiviral immunity.
The potential of gene expression profiling as a marker of treatment response in patients with IPF requires further study.